Summary
Background Throughout the COVID-19 pandemic, human mobility has played a central role in shaping disease transmission. In this study, we develop a mechanistic model to calculate disease incidence from commercially-available US mobility data over the course of 2020. We use it to study, at the US state level, the lag between infection and case report. We examine the evolution of per-contact transmission probability, and its dependence on mean air temperature. Finally, we evaluate the potential of the model to produce short-term incidence forecasts from mobility data.
Methods We develop a mechanistic model that relates COVID-19 incidence to time series contact index (CCI) data collected by mobility data vendor Cuebiq. From this, we perform maximum-likelihood estimates of the transmission probability per CCI event. Finally, we retrospectively conduct forecasts from multiple dates in 2020 forward.
Findings Across US states, we find a median lag of 19 days between transmission and case report. We find that the median transmission probability from May onward was about 20% lower than it was during March and April. We find a moderate, statistically significant negative correlation between mean state temperature and transmission probability, r = − .57, N = 49, p = 2 × 10−5. We conclude that for short-range forecasting, CCI data would likely have performed best overall during the first few months of the pandemic.
Interpretation Our results are consistent with associations between colder temperatures and stronger COVID-19 burden reported in previous studies, and suggest that changes in the per-contact transmission probability play an important role. Our model displays good potential as a short-range (2 to 3 week) forecasting tool during the early stages of a future pandemic, before non-pharmaceutical interventions (NPIs) that modify per-contact transmission probability, principally face masks, come into widespread use. Hence, future development should also incorporate time series data of NPI use.
Competing Interest Statement
EWT, SSC GG, LC, RA and CM are employees of Sanofi, a company which manufactures a COVID-19 vaccine. All other authors declare no competing interests
Funding Statement
Some of the data used in this study was purchased by Sanofi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
